These solutions leverage the power of Illumina's leading NovaSeq X series platform and will enable researchers to derive breakthrough insights around the drivers of disease. The company will also ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...

Illumina will seek to cut $100 million in expenses ... multimodal software platform that runs on its current NextSeq and NovaSeq hardware. The company is also developing what it describes as ...

Users will go through a chemistry workflow to permeabilize, hybridize, and make a cDNA library that will be fully compatible with illumina sequencers—both NovaSeq and NextSeq. Users can also ...

Illumina is raising the curtain on its upcoming ... The company said its spatial technology will run on its current NextSeq and NovaSeq hardware through a new multimodal software platform, with ...

This partnership combines Illumina’s Single Cell Prep and NovaSeq™ X Plus platform with Broad Clinical Labs’ expertise, promising to transform the scale of single-cell sample processing.

Further innovation, like the NovaSeq, continued to push down these costs, and Illumina expects its new NovaSeq X Series to enable the $100 genome, which could greatly increase the accessibility of ...

While Illumina has faced pricing headwinds, particularly with the NovaSeq X transition, some analysts believe that a significant portion of these challenges have already been absorbed. This could ...

The collaboration combines Illumina's Single Cell Prep and NovaSeq™ X Plus platform with Broad Clinical Labs' expertise in high-throughput workflows and advanced techniques like Perturb-seq and CRISPR ...